These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 23640345

  • 1. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
    Ton GN, Banaszynski ME, Kolesar JM.
    Am J Health Syst Pharm; 2013 May 15; 70(10):849-55. PubMed ID: 23640345
    [Abstract] [Full Text] [Related]

  • 2. Vandetanib for the treatment of medullary thyroid carcinoma.
    Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M.
    Ann Pharmacother; 2014 Mar 15; 48(3):387-94. PubMed ID: 24259657
    [Abstract] [Full Text] [Related]

  • 3. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K, Komoda M, Tomomatsu J, Okamoto T, Horiuchi K, Tsuji A, Ito Y, Todo T, Rito K, Takahashi S.
    Endocr Pract; 2017 Feb 15; 23(2):149-156. PubMed ID: 27819766
    [Abstract] [Full Text] [Related]

  • 4. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P, Carroll C, Hamilton J, Kaltenthaler E, Wong R, Wadsley J, Moss L, Balasubramanian S.
    Health Technol Assess; 2019 Feb 15; 23(8):1-144. PubMed ID: 30821231
    [Abstract] [Full Text] [Related]

  • 5. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
    Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ.
    J Clin Oncol; 2012 Jan 10; 30(2):134-41. PubMed ID: 22025146
    [Abstract] [Full Text] [Related]

  • 6. Vandetanib therapy in medullary thyroid cancer.
    Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D.
    Drugs Today (Barc); 2012 Nov 10; 48(11):723-33. PubMed ID: 23170308
    [Abstract] [Full Text] [Related]

  • 7. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
    Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ.
    Lancet Oncol; 2012 Sep 10; 13(9):897-905. PubMed ID: 22898678
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ, Seib CD, Gosnell J.
    Curr Opin Oncol; 2013 Jan 10; 25(1):39-43. PubMed ID: 23202050
    [Abstract] [Full Text] [Related]

  • 11. Vandetanib: in medullary thyroid cancer.
    Frampton JE.
    Drugs; 2012 Jul 09; 72(10):1423-36. PubMed ID: 22715896
    [Abstract] [Full Text] [Related]

  • 12. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R.
    J Clin Endocrinol Metab; 2010 Jun 09; 95(6):2664-71. PubMed ID: 20371662
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
    Chougnet CN, Schlumberger M, Leboulleux S, Baudin E.
    Bull Cancer; 2014 Sep 09; 101(9):891-5. PubMed ID: 25296193
    [Abstract] [Full Text] [Related]

  • 15. Selective use of vandetanib in the treatment of thyroid cancer.
    Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A.
    Drug Des Devel Ther; 2015 Sep 09; 9():3459-70. PubMed ID: 26170630
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH, Robinson BG, Learoyd DL.
    Expert Opin Drug Saf; 2016 Aug 09; 15(8):1107-13. PubMed ID: 27301016
    [Abstract] [Full Text] [Related]

  • 18. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF, Adam P, Frank-Raue K, Raue F, Berg E, Hoster E, Allelein S, Schott M, Kroiss M, Spitzweg C.
    Thyroid; 2021 Mar 09; 31(3):459-469. PubMed ID: 32781914
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C.
    J Clin Oncol; 2012 Apr 01; 30(10):1114-21. PubMed ID: 22370318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.